



Europharma is a Contract Research Organization with a professional team of over 30 specialists. The company specializes in PASS, PAES and Market Research. The company's high quality standards in the execution of trials has been consistently proven during our 17 years in the industry. Europharma is a strategic solutions provider and a safe alternative to largest pharmaceutical companies. We support with our services 6 of the Top 20 Global Pharma companies.

Studies
300



Patients
1 212 100



Investigators
60 621



ADRs
9 960



PASS & PAES Studies

Europharma has successfully conducted over 50 safety studies in most of therapeutic areas, in which we:

contracted over:

23 826

Investigators



and recruited over:

476 520


Patients



Our investigators are members of Research Quality Association and ICH GCP certified.

Therapeutic areas


Therapeutic areas covered by our PASS Studies:



Adverse Drug Reaction

Europharma supports medical and pharmacovigilance departments of pharmaceutical companies.

We are the unique provider of online ADRs reporting system in polish market at dzialanieniepozadane.com. Our goal is to develop and expand it for Central and Eastern European countries.



* ADRs in Poland reported 2010-2014



We care

Instead of buying gifts and gadgets we decided to support orphans and children from poor families to help them in developing social skills and provide them proper education. A smile on their faces and awareness of the increasing successes are our greatest reward.

We support:

Marcel 14 years old

Gabrysia 15 years old

Marta 15 years old

Oliwia 13 years old



Some of our publications

- Evaluation of the Safety Profile of Zolafren®, a Generic Olanzapine Formulation, in Patients with Bipolar Disorder: A Post-Authorization Safety Study, **Advances in Therapy**, DOI 10.1007/s12325-015-0210-8, May 2015.
- Depressive symptoms in patients diagnosed with benign prostatic hyperplasia, **International Urology and Nephrology** 2015; 47(3): 431-440.
- Quality of life (QOL) evaluation after coronary syndrome with simultaneous clopidogrel treatment, **Archives of Medical Science** 2014 Feb 24; 10(1): 33-38.
- Blood pressure for optimal health-related quality of life in hypertensive patients, **Journal of Hypertension** 2013, 31:000-000.
- Safety and tolerance of generic rosuvastatin formulation (Suvardio®) in therapy of patients with primary hypercholesterolemia and mixed dyslipidemia – results of a post-marketing, non-randomized, non-interventional, multicenter survey in outpatient treatment, **Problemy medycyny rodzinnej**, December 2013, VOL. XV, No. 4.
- Safety and tolerance of Plavocorin®, a generic clopidogrel formulation in therapy of patients after acute coronary syndrome – results of a post-marketing, non-randomized, non-interventional, multicenter survey in outpatient treatment, **Problemy Medycyny Rodzinnej**, May 2013, VOL. XIV, No. 4.
- Safety and tolerance of generic levetiracetam formulation (Vetira®) in Polish patients diagnosed with epilepsy – results of a post-marketing, non-randomized, non-interventional, multicenter survey in outpatient practice, **Review of Clinical Neuropsychiatry** VOL. 5 (NR 3)/2013: 00.
- Resistant hypertension in visceral obesity, **European Journal of Internal Medicine** 23 (2012) 643-648.
- Safety and tolerance of generic olanzapine formulation (Zapilux®) in therapy of patients with schizophrenia – results of a post-marketing, non-randomized, non-interventional, multicenter survey in outpatient treatment, **Problemy Medycyny Rodzinnej**, September 2012, VOL. XIV, No. 3
- Factors that favor the occurrence of cough in patients treated with ramipril – A pharmacoepidemiological study, **Med Sci Monit**, 2012; 18(9): P121-28.
- Effects of angiotensin-converting enzyme inhibitors lowering blood pressure – are they important for doctors?, **Pharmacological Reports** 2011, 63, 740-751.
- Education using SMS increases efficacy of treatment of hypertensive patients, **Arterial Hypertension** 2009, vol. 13, no 3, pages 147-157.



Europharma
6, Krzywa Street
40-061 Katowice
Poland
Tel: +48 519 333 448
+48 519 333 440
www.europharma.edu.pl
www.adrreporting.com

